Role of Viscoelastometric Testing in the Development and Validation of a Clinical-biological Score for Predicting Bleeding in Patients With Malignant Haematological Disorders and Severe Thrombocytopenia (VISCOTHEM-2)
The goal of this single-center, non-controlled, non-randomized exploratory clinical trial is To develop and validate a clinical-biological score (VISCOTHEM score) incorporating viscoelastometric tests parameters; based on an association study, and to establish a threshold that enables the prediction of the immediate risk of bleeding in haematology patients with severe thrombocytopenia (<20 G/L); with a view to selecting a population with a residual risk of bleeding of zero (NPV ≥ 95%, to achieve a residual probability of bleeding < 5%).
The score may incorporate variables identified in the literature as having a plausible causal relationship with the occurrence of bleeding (14,15), as well as viscoelastometric tests parameters, conventional haemostasis parameters and relevant clinical parameters. .
Participants will undergo an additional blood sample to standard care. The total volume of blood drawn will be 21.1 mL. The following analyses will be performed: Quantra®, Rotem®, blood count, platelets, immature platelet count, plasma prothrombin time, activated partial thromboplastin time, International Normalized Ratio, fibrinogen, urea, creatinin, albumin.
연구 개요
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: Marion GHIDI
- 전화번호: +33450637031
- 이메일: mghidi@ch-annecygenevois.fr
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
샘플링 방법
연구 인구
The patients included will be selected from the entire cohort of patients with haematological malignancies:
- those admitted to the haematology day unit for treatment or assessment,
- or patients admitted to the haematology inpatient ward,
- or patients being monitored in the haematology outpatient clinic.
설명
Inclusion Criteria:
- Adult patients;
- Who have been informed about the study and have freely given their informed consent to participate in the study;
- With a malignant haematological disorder or bone marrow failure, whether treated or untreated and at any stage of treatment;
- With central thrombocytopenia strictly below 20 G/L in a blood sample taken less than 72 hours ago and not having received a transfusion since;
- Admitted to a haematology day unit or inpatient ward, or being followed up at a haematology outpatient clinic;
- With or without active bleeding;
- Affiliated with or covered by a social security scheme.
Exclusion Criteria:
- Patients who have received at least one of the following treatments:
- Antiplatelet agents within 7 days prior to enrolment,
- Vitamin K antagonists within 7 days prior to enrolment,
- Direct oral anticoagulants within 72 hours prior to enrolment,
- Low molecular weight heparin within 24 hours prior to inclusion,
- Unfractionated heparin within 6 hours prior to inclusion,
- Bruton's tyrosine kinase inhibitor (ibrutinib, zanubrutinib or acalabrutinib) within 72 hours prior to inclusion;
- Patients with a history of thrombopathy;
- Patients with a history of haemostatic disorders carrying a risk of haemorrhage or thrombosis;
- Thrombocytopenia associated with immune thrombocytopenic purpura or disseminated intravascular coagulation;
- Patients already enrolled in the study;
- Pregnant or breastfeeding women;
- Patients under guardianship or curatorship;
- Patients who do not understand French;
- Patients under judicial protection.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
Intervention (additional blood sample)
|
A blood sample will be taken from all patients included in the study.
This blood sampling is an added act of the study.
It will be performed as soon as possible after inclusion in the study.
The total volume of blood drawn will be 21.1 mL.
The following analyses will be performed: Quantra®, Rotem®, blood count, platelets, immature platelet count, plasma prothrombin time, activated partial thromboplastin time, International Normalized Ratio, fibrinogen, Urea, Creatinine, Albumin.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Identification of factors associated with bleeding among clinical and laboratory parameters
기간: At baseline, before platelet transfusion
|
Clinical parameters : Age, Sex, BMI, systolic and diastolic blood pressure, presence of mucositis, presence of a lesion with haemorrhagic potential, bleeding within the previous 5 days, fever associated with an infection or an episode of febrile neutropenia, transplant within the previous 100 days Laboratory parameters : viscoelastic test parameters, white blood cell count, Haemoglobin, Platelet and immature platelet counts, Urea, Creatinine, Albumin, Standard haemostasis (APTT, INR, Fibrinogen)
|
At baseline, before platelet transfusion
|
|
Apply a multivariate regression model to develop the VISCOTHEM score for predicting immediate bleeding (WHO score ≥ 1), based on the coefficients of the factors associated with bleeding
기간: At baseline, before platelet transfusion
|
At baseline, before platelet transfusion
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Stratification and comparison of performance and score calibration depending on whether the viscoelastic test result is obtained using ROTEM® or Quantra®.
기간: At baseline, before platelet transfusion
|
To propose a score capable of processing a viscoelastic test result from either ROTEM® or Quantra®,
|
At baseline, before platelet transfusion
|
|
Describe the presence of bleeding according to the WHO classification (WHO score ≥1) and WHO bleeding grade, where applicable
기간: 72 hours after blood sample
|
72 hours after blood sample
|
|
|
Describe the presence of platelet transfusion
기간: 72 hours after blood sample
|
72 hours after blood sample
|
|
|
Describe the Vital status or loss of follow-up, where applicable
기간: 72 hours after blood sample
|
72 hours after blood sample
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
기타 연구 ID 번호
- 24-10
- 2026-A00535-46 (기타 식별자: ID-RCB (ANSM))
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
Additional blood sample에 대한 임상 시험
-
Haydarpasa Numune Training and Research Hospital완전한
-
University Hospital, Rouen모병
-
The University of QueenslandBecton, Dickinson and Company모병
-
Ischemia Care LLC완전한허혈성 뇌졸중 | 심방세동 | 혈전성 뇌졸중 | 일시적인 허혈 발작 | 심장색전성 뇌졸중 | 뇌저동맥의 뇌졸중 | 일시적인 뇌혈관 사건미국